Recent Developments in Prostate Cancer Care
Recent Developments in Prostate Cancer | MedPage Today
A roundup of the practice-shaping trial data reported between February and June 2026 — ASCO GU, AUA, and the ASCO Annual Meeting — prepared for the IPCSG community
BLUF — Bottom Line Up Front
Six studies reported in the first half of 2026 collectively push treatment earlier and make it more precisely targeted to tumor biology. For men with high-risk localized disease, adding a year of apalutamide around surgery cut the risk of metastasis by 20% (PROTEUS). For men with hormone-sensitive metastatic disease carrying DNA-repair gene mutations, adding a PARP inhibitor (talazoparib) to enzalutamide cut progression risk by roughly half (TALAPRO-3). Darolutamide continues to distinguish itself on two fronts — real-world-comparable efficacy against a historical ADT-alone benchmark (ARASEC) and measurably less cognitive decline than enzalutamide (ARACOG). In first-line metastatic castration-resistant disease with BRCA1/2 or ATM alterations, combining abiraterone with olaparib produced a median overall survival past five years (BRCAAway). And for men who want to avoid the classic hot-flash burden of LHRH agonists, transdermal estradiol patches performed as well as standard injections in a large UK trial (PATCH/STAMPEDE-1). No new prostate-cancer-drug court filings or FDA safety actions of note were identified in this period; the one regulatory item worth flagging is a June 26, 2026 tentative FDA approval of a generic enzalutamide, a step toward eventual cost relief once patents allow it to launch. As always, none of this changes anyone's individual treatment plan without a conversation with your own oncology team — but it is a genuinely active season for the field.
1. High-Risk Localized Disease: A New Standard Emerges — PROTEUS
Perioperative Apalutamide + ADT vs. ADT Alone Phase 3, n=2,109
For decades, men undergoing radical prostatectomy for high-risk localized or locally advanced disease have had no systemic therapy proven to meaningfully change their long-term trajectory around the time of surgery. The PROTEUS trial, the largest therapeutic study ever conducted in localized prostate cancer, tested one year of apalutamide (an androgen receptor pathway inhibitor already approved for metastatic and non-metastatic castration-resistant disease) added to ADT, given both before and after surgery, against ADT plus placebo.
- Pathologic complete response or minimal residual disease at surgery: 8.9% with apalutamide vs. 1.0% with placebo — roughly a nine-fold increase.
- Five-year metastasis-free survival: 78.2% with apalutamide vs. 73.5% with placebo, a statistically significant 20% reduction in risk of metastasis or death (hazard ratio 0.80).
- Event-free survival, time to subsequent therapy, and need for salvage/adjuvant radiation all favored the apalutamide arm; investigators noted most men recovered testosterone within months of finishing the one-year course.
- Grade 3/4 adverse events were somewhat more common with apalutamide (about 39.5–39.6%) than placebo (31%), with lymphocele and urinary tract infection the most frequent events in both arms.
Lead investigator Mary-Ellen Taplin, MD (Dana-Farber Cancer Institute) described the combination as warranting consideration as a new standard of care for this population, while formal discussant Declan Murphy, MB BCh (Peter MacCallum Cancer Centre) cautioned that high-risk disease is not monolithic — some men with favorable-prognosis "high-risk" features may not need intensification. The manufacturer, Johnson & Johnson, has not yet announced a regulatory filing timeline for the perioperative indication; that is the item worth watching next.
2. Metastatic Hormone-Sensitive Disease with DNA-Repair Mutations — TALAPRO-3
Talazoparib + Enzalutamide vs. Placebo + Enzalutamide Phase 3, n=599
TALAPRO-3 tested whether adding the PARP inhibitor talazoparib to enzalutamide would benefit men with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) whose tumors carry homologous recombination repair (HRR) gene alterations — the same biology relevant to genomic subtyping discussions many IPCSG members have followed.
- Radiographic progression-free survival: median not reached with the combination vs. 45.8 months with enzalutamide alone (hazard ratio 0.481) — a 52% reduction in risk of progression or death.
- Among men with BRCA1/2 mutations specifically, the risk reduction was even larger, at 63%.
- Overall survival data are still maturing but trended in favor of the combination (74 vs. 91 deaths).
- Anemia (71%), fatigue (28%), and low neutrophil counts (27%) were the most common side effects on the combination — consistent with the known profile of PARP inhibitors.
Talazoparib plus enzalutamide already carries FDA approval for HRR-mutated metastatic castration-resistant disease. TALAPRO-3 tests the same combination one stage earlier, while hormone therapy still works. Pfizer has indicated it intends to discuss these results with regulators to explore an earlier-line indication, though no formal filing has been announced as of this writing. The trial's lead investigator, Neeraj Agarwal, MD (University of Utah Huntsman Cancer Institute), emphasized that the results reinforce the importance of upfront genomic testing to identify which patients carry HRR alterations before choosing a first-line regimen.
3. Real-World-Anchored Evidence for Darolutamide — ARASEC
Darolutamide + ADT vs. Propensity-Matched Historical Control (CHAARTED) Phase 2, external-control design
ARASEC took a methodologically distinct approach: rather than a placebo-controlled arm, investigators prospectively treated U.S. patients with darolutamide plus ADT and statistically matched them, using propensity scoring on age, performance status, disease burden, prior local therapy, Gleason score, and baseline PSA, to men who received ADT alone in the historic Phase 3 CHAARTED trial.
- Progression or death per CHAARTED criteria was reduced by 71% with darolutamide plus ADT versus the matched ADT-alone control (hazard ratio 0.29).
- Two-year overall survival: 89% with darolutamide plus ADT vs. 80% in the historical control — notable given that the darolutamide-plus-ADT group had a far lower subsequent rate of additional life-prolonging therapy (26% vs. 65%), suggesting the initial regimen itself was doing more of the work.
- Safety was reported descriptively for the darolutamide arm only, since the historical control did not systematically collect comparable data; 8% of darolutamide-treated patients discontinued due to treatment-related adverse events.
Principal investigator Rana McKay, MD, of UC San Diego (a name IPCSG readers with San Diego-area ties will recognize) called this the first prostate cancer study to use propensity-score matching against an external Phase 3 control arm, describing it as a template for accelerating evidence generation when it is impractical to run a placebo-controlled trial. The obvious limitation, which both Bayer's release and independent commentary acknowledged, is that propensity matching can only adjust for measured variables — unmeasured confounders and the passage of time between trials (changes in imaging, supportive care, and definitions) remain real caveats.
4. Cognitive Function on Hormonal Therapy — ARACOG
Darolutamide vs. Enzalutamide, Cognitive Outcomes Phase 2, n=95 evaluable
This is the first randomized U.S. trial to make cognitive function the primary endpoint when comparing these two androgen receptor pathway inhibitors — a question of practical importance given prior signals that enzalutamide carries a higher risk of neurological side effects such as falls and seizures than darolutamide, which does not cross the blood-brain barrier to the same degree.
- Cognition was measured with the CANTAB battery (memory, spatial working memory, visual memory, processing speed, and executive function) at baseline, 12, 24, and 48 weeks.
- Median decline in the most-affected cognitive domain at 24 weeks: −15.8% with darolutamide vs. −36.1% with enzalutamide (p = 0.009).
- Darolutamide was favored in 4 of 5 individual cognitive modules; darolutamide-treated patients' scores in some modules actually rose slightly over baseline, consistent with a normal test-retest learning effect rather than decline.
Lead author Alicia Morgans, MD, MPH (Dana-Farber Cancer Institute) was careful to frame the result appropriately for patients: none of the participants met criteria for a diagnosed cognitive disorder, and CANTAB is a research tool, not a diagnostic test. Even so, ASCO president Eric Small, MD, called cognitive loss "devastating" for patients living with the disease long-term, and noted the finding may reasonably factor into the choice between these two otherwise similarly effective drugs when both are options.
5. First-Line Metastatic Castration-Resistant Disease with BRCA1/2 or ATM — BRCAAway
Abiraterone + Prednisone + Olaparib vs. Either Agent Alone Phase 2, n=61 randomized
BRCAAway asked whether combining a PARP inhibitor with an androgen receptor pathway inhibitor up front, rather than sequencing them, produces better outcomes in men with treatment-naive metastatic castration-resistant prostate cancer carrying BRCA1/2 or ATM alterations.
- Median overall survival: 68 months with the triplet (abiraterone + prednisone + olaparib) vs. 37 months with abiraterone/prednisone alone and 28 months with olaparib alone.
- Hazard ratio for death, combination vs. abiraterone alone: 0.39; vs. olaparib alone: 0.51 — both favoring the upfront combination, even though crossover to the combination was permitted for men who progressed on a single agent.
- The combination was described as well tolerated, allowing some patients to remain on treatment for years.
Presenter Maha Hussain, MD (Northwestern University) called the result "remarkable," while independent discussant Evan Yu, MD (Fred Hutch Cancer Center) urged caution given the small sample size and some imbalance in baseline disease characteristics between arms — this is not yet evidence that every man with a BRCA1/2 or ATM alteration should automatically receive combination therapy first-line, but it strengthens the rationale for considering it in patients with aggressive-appearing disease. A related, larger Phase 3 trial (PROfound, published in 2020) had already established that olaparib alone extends survival compared with a second novel hormonal agent in this biomarker-defined population; BRCAAway extends that story toward upfront combination.
6. An Alternative to Injections — Transdermal Estradiol (PATCH/STAMPEDE-1)
Estradiol Patches vs. LHRH Agonists Phase 3 noninferiority, n=1,360
This long-running UK trial (enrollment spanned 2007–2022) compared transdermal estradiol patches to standard LHRH-agonist injections in men with locally advanced, non-metastatic prostate cancer, testing whether estrogen-based testosterone suppression is a viable, more tolerable alternative to conventional ADT.
- Three-year metastasis-free survival: 87.1% with estradiol patches vs. 85.9% with LHRH agonists — meeting the trial's noninferiority margin.
- Five-year overall survival did not differ significantly (81.1% vs. 79.2%).
- Hot flashes and other vasomotor symptoms occurred about twice as often with LHRH agonists (89% vs. 44%); gynecomastia occurred about twice as often with the estradiol patches (85% vs. 42%) — a genuine tradeoff rather than a clear winner on side effects.
Estradiol patches are not currently licensed for prostate cancer treatment in the UK or the U.S., and the study authors note that University College London's technology transfer office is now working with potential manufacturers on licensing so the option could become more widely available. For men who find hot flashes intolerable on standard ADT, this trial provides the strongest evidence yet that a patch-based alternative controls the cancer just as well — a conversation worth having with your urologist or medical oncologist if vasomotor symptoms have been a significant quality-of-life issue.
7. Regulatory and Access Notes
- Generic enzalutamide: On June 26, 2026, the FDA granted tentative approval to Lupin Limited's generic enzalutamide tablets (40 mg, 80 mg, 120 mg, and 160 mg). Tentative approval confirms the product meets FDA quality, safety, and efficacy standards but does not permit commercial launch until relevant patent and exclusivity barriers are resolved — a development to watch for eventual cost relief on this widely used drug.
- Litigation and court filings: No prostate-cancer-drug-specific court filings, safety litigation, or enforcement actions relevant to the therapies discussed above were identified as of this writing. Readers should treat the absence of findings as a snapshot of late June 2026 rather than a permanent state of affairs.
Verified Sources
- Taplin ME, Gleave M, Shore ND, et al. Perioperative Apalutamide in High-Risk Localized Prostate Cancer. N Engl J Med. 2026. doi:10.1056/NEJMoa2603878. Presented as Abstract LBA1, 2026 ASCO Annual Meeting.
Johnson & Johnson press release: jnj.com · Dana-Farber Cancer Institute release: dana-farber.org · ASCO Post coverage: ascopost.com · ASCO patient summary: asco.org - Agarwal N, Matsubara N, Azad A, et al. TALAPRO-3: Talazoparib +
Enzalutamide vs. Placebo + Enzalutamide in HRR Gene-Altered Metastatic
Castration-Sensitive Prostate Cancer. J Clin Oncol. 2026;44(suppl 17):LBA5007. Published simultaneously in N Engl J Med. doi:10.1056/NEJMoa2604126.
Abstract: ascopubs.org · CancerNetwork coverage: cancernetwork.com · Managed Healthcare Executive coverage: managedhealthcareexecutive.com - McKay RR, et al. Phase II ARASEC Trial: Darolutamide + ADT vs.
Propensity-Matched CHAARTED Control in Metastatic Castration-Sensitive
Prostate Cancer. Presented at the 2026 American Urological Association
Annual Meeting.
Bayer official release: bayer.com · BioSpace coverage: biospace.com - Morgans AK, et al. ARACOG (AFT-47): A Randomized Phase II Study of Cognitive Effects of Darolutamide vs. Enzalutamide. J Clin Oncol. 2026;44(suppl 16):abstr 5005. Alliance for Clinical Trials in Oncology.
ASCO Post coverage: ascopost.com · Bayer release: bayer.com · ecancer coverage: ecancer.org - Hussain MH, Kocherginsky M, Paller CJ, et al. Overall Survival
from the Phase 2 BRCAAway Trial of Abiraterone, Olaparib, or Abiraterone
+ Olaparib in First-Line mCRPC with DNA Repair Defects. Presented at
the 2026 ASCO Genitourinary Cancers Symposium, Abstract 16. J Clin Oncol. 2026;44(7_suppl):16.
Abstract: ascopubs.org · ASCO Post coverage: ascopost.com · Prior published trial data: Hussain M, et al. Clin Cancer Res. 2024;30(19):4318-4328. - Langley RE, Gilbert DC, Mangar S, et al. Transdermal Estradiol Patches in Locally Advanced Prostate Cancer (PATCH/STAMPEDE-1). N Engl J Med. 2026;394(16):1595-1607. doi:10.1056/NEJMoa2511781.
Full text: nejm.org · UCL news release: ucl.ac.uk · ASCO Post coverage: ascopost.com - Bankhead C. Recent Developments in Prostate Cancer. MedPage Today. 2026 (background source synthesizing the above trials).
medpagetoday.com - U.S. Food and Drug Administration. Tentative Approval, Lupin
Limited generic enzalutamide tablets (40 mg, 80 mg, 120 mg, 160 mg).
June 26, 2026.
Reported in: TechTimes, "Prostate Cancer Drug Cuts Progression Risk by 52%: Genetic Test Required," techtimes.com
This article summarizes publicly reported clinical trial data and conference presentations for general patient education purposes. It is not a substitute for individualized medical advice. Reported statistics (hazard ratios, survival percentages, adverse event rates) are drawn from the sources cited above as of late June 2026 and may be revised as trials mature or undergo peer review beyond preliminary conference presentation. Members should discuss any of these therapies with their own oncology care team before making treatment decisions.
Prepared for the Informed Prostate Cancer Support Group (IPCSG) newsletter.
Comments
Post a Comment